Accelerating and expanding the therapeutic potential of ERAP1 inhibition in cancer

加速和扩大 ERAP1 抑制在癌症中的治疗潜力

• 批准号: 92627
• 金额: $ 110.58万
• 依托单位: GREY WOLF THERAPEUTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=92627
• 关键词: Accelerating; expanding; therapeutic; potential; ERAP1

Grey Wolf Therapeutics is developing a next-generation approach to cancer immunotherapy that is more effective than existing treatments and can be applied to a much wider variety of cancers.Breakthroughs in immunotherapy have been ground-breaking in the treatment of some cancers, with great benefits in some patients with advanced disease, in some cases extending and improving the life of patients by many years. However, most types of cancer are not controlled by these therapies, and therefore there remains a huge need to develop new medicines as cancer rates continue to grow. Recent research has shown that the visibility of a tumour to the immune system is one of the most important factors that decides whether it will progress and grow.Tumours that show a high number of 'non-self' components at the cell surface called neoantigens are particularly sensitive to current immunotherapies because they are more visible and likely to be recognized by the immune system as 'foreign'. However, most cancers have low numbers of neoantigens on their surface and therefore immunotherapies are not very effective in these cases. The immune system simply doesn't recognise that the cells should be eliminated. The future of cancer therapy requires new medicines that can address the tumour visibility problem.Grey Wolf has developed an innovate medicine that significantly alters the neoantigens presented on the cancer cell surface, illuminating them to the immune system, which is now able to recognise that the cells should be destroyed. This completely novel mode of action is active across the spectrum of cancer types and as such has the potential to provide huge benefits to thousands of cancer patients who currently have no effective treatment options available to them.

灰太狼正在开发新一代的癌症免疫治疗方法，这种方法比现有的治疗方法更有效，可以应用于更广泛的癌症。免疫治疗的突破性进展在某些癌症的治疗中具有突破性意义，对某些晚期疾病患者有很大的益处，在某些情况下，延长和改善患者的生命多年。然而，大多数类型的癌症并不受这些疗法的控制，因此随着癌症发病率的持续增长，仍然需要开发新的药物。最近的研究表明，肿瘤对免疫系统的可见性是决定其是否会发展和生长的最重要因素之一。在细胞表面显示大量“非自身”成分（称为新抗原）的肿瘤对当前的免疫疗法特别敏感，因为它们更容易被免疫系统识别为“外来”。然而，大多数癌症在其表面上具有低数量的新抗原，因此免疫疗法在这些情况下不是非常有效。免疫系统根本不认识到这些细胞应该被清除。未来的癌症治疗需要能够解决肿瘤可见性问题的新药物。灰太狼开发了一种创新药物，可以显著改变癌细胞表面的新抗原，将其照亮免疫系统，免疫系统现在能够识别细胞应该被摧毁。这种全新的作用模式在各种癌症类型中都很活跃，因此有可能为成千上万目前没有有效治疗方案的癌症患者提供巨大的益处。